1 day Ago By ABMN Staff
BrainsWay ( NASDAQ:BWAY – Get Free Report ) ‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $16.00 price objective on the stock.
HC Wainwright’s price target suggests a potential upside of 93.24% from the company’s previous close. Separately, Northland Securities upped their price objective on shares of BrainsWay from $9.
00 to $11.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. Check Out Our Latest Stock Analysis on BWAY BrainsWay Stock Down 1.
9 % BrainsWay ( NASDAQ:BWAY – Get Free Report ) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share for the quarter.
BrainsWay had a net margin of 1.67% and a return on equity of 1.45%.
The firm had revenue of $10.01 million for the quarter, compared to analysts’ expectations of $9.40 million.
During the same quarter last year, the company posted ($0.05) EPS. On average, research analysts anticipate that BrainsWay will post 0.
06 earnings per share for the current year. Hedge Funds Weigh In On BrainsWay Several hedge funds have recently made changes to their positions in BWAY. Perritt Capital Management Inc purchased a new stake in BrainsWay in the second quarter worth $121,000.
Acadian Asset Management LLC boosted its holdings in shares of BrainsWay by 48.1% during the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after buying an additional 84,371 shares in the last quarter.
Rhumbline Advisers grew its position in shares of BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after buying an additional 1,695 shares during the period.
Virtu Financial LLC bought a new position in shares of BrainsWay in the 1st quarter worth about $60,000. Finally, Essex Investment Management Co. LLC lifted its position in BrainsWay by 37.
5% during the 1st quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock valued at $1,718,000 after acquiring an additional 88,593 shares during the period.
30.11% of the stock is owned by hedge funds and other institutional investors. BrainsWay Company Profile ( Get Free Report ) BrainsWay Ltd.
develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. Featured Stories Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.
com's FREE daily email newsletter ..
